WO2001090413A3 - Method and markers for prognosticating efficacy of anticancer agents - Google Patents

Method and markers for prognosticating efficacy of anticancer agents Download PDF

Info

Publication number
WO2001090413A3
WO2001090413A3 PCT/US2001/016004 US0116004W WO0190413A3 WO 2001090413 A3 WO2001090413 A3 WO 2001090413A3 US 0116004 W US0116004 W US 0116004W WO 0190413 A3 WO0190413 A3 WO 0190413A3
Authority
WO
WIPO (PCT)
Prior art keywords
markers
anticancer agents
prognosticating
efficacy
prognosticating efficacy
Prior art date
Application number
PCT/US2001/016004
Other languages
French (fr)
Other versions
WO2001090413A2 (en
Inventor
Rafael Rosell
Mariano Monzo
Original Assignee
Bristol Myers Squibb Co
Rafael Rosell
Mariano Monzo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Rafael Rosell, Mariano Monzo filed Critical Bristol Myers Squibb Co
Priority to AU2001261725A priority Critical patent/AU2001261725A1/en
Publication of WO2001090413A2 publication Critical patent/WO2001090413A2/en
Publication of WO2001090413A3 publication Critical patent/WO2001090413A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods and markers for prognosticating the efficacy of anti-cancer agents in patients suffering from cancer by detection of mutant tubulin genes are provided.
PCT/US2001/016004 2000-05-19 2001-05-17 Method and markers for prognosticating efficacy of anticancer agents WO2001090413A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001261725A AU2001261725A1 (en) 2000-05-19 2001-05-17 Method and markers for prognosticating efficacy of anticancer agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57478800A 2000-05-19 2000-05-19
US09/574,788 2000-05-19

Publications (2)

Publication Number Publication Date
WO2001090413A2 WO2001090413A2 (en) 2001-11-29
WO2001090413A3 true WO2001090413A3 (en) 2003-04-17

Family

ID=24297636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016004 WO2001090413A2 (en) 2000-05-19 2001-05-17 Method and markers for prognosticating efficacy of anticancer agents

Country Status (2)

Country Link
AU (1) AU2001261725A1 (en)
WO (1) WO2001090413A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425038D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
ITTO20130501A1 (en) * 2013-06-18 2014-12-19 Consiglio Nazionale Ricerche PROCEDURE AND KIT FOR FOOD ANALYSIS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074671A1 (en) * 1999-06-02 2000-12-14 Bristol-Myers Squibb Company Method and markers for prognosticating efficacy of anticancer agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074671A1 (en) * 1999-06-02 2000-12-14 Bristol-Myers Squibb Company Method and markers for prognosticating efficacy of anticancer agents

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GIANNAKAKOU P ET AL: "Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 27, 4 July 1997 (1997-07-04), pages 17118 - 17125, XP002111288, ISSN: 0021-9258 *
GIANNAKAKOU PARASKEVI ET AL: "A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2904 - 2909, XP002189845, ISSN: 0027-8424 *
JORDAN A ET AL: "TUBULIN AS A TARGET FOR ANTICANCER DRUGS: AGENTS WHICH INTERACT WITH THE MITOTIC SPINDLE", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 18, no. 4, 1998, pages 259 - 296, XP000886283, ISSN: 0198-6325 *
KAVALLARIS MARIA ET AL: "Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 5, 1997, pages 1282 - 1293, XP002212781, ISSN: 0021-9738 *
KOWALSKI ET AL: "Activities of the microtubule-stabilizing agents Epothilones A and B with purified tubulin and in cells resistant to Paclitaxel (Taxol)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 4, 24 January 1997 (1997-01-24), pages 2534 - 2541, XP002111279, ISSN: 0021-9258 *
MONZO M ET AL: "BETA-TUBULIN GENE MUTATIONS INDUCE TAXOL CHEMORESISTANCE IN NON-SMALL CELL LUNG CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 38, no. 38, March 1997 (1997-03-01), pages 251,AN1689, XP001084241, ISSN: 0197-016X *
MONZO M ET AL: "PACLITAXEL RESISTANCE IN NON-SMALL-CELL LUNG CANCER ASSOCIATED WITH BETA-TUBULIN GENE MUTATIONS", JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 17, no. 6, June 1999 (1999-06-01), pages 1786 - 1793, XP001088343 *
ROSELL R ET AL: "Predictive molecular markers in non-small cell lung cancer.", CURRENT OPINION IN ONCOLOGY. UNITED STATES MAR 2001, vol. 13, no. 2, March 2001 (2001-03-01), pages 101 - 109, XP001132011, ISSN: 1040-8746 *
SALE SANJA ET AL: "Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 3, January 2002 (2002-01-01), January, 2002, pages 215 - 225, XP008011369, ISSN: 1535-7163 *
TSURUTANI JUNJI ET AL: "Mutational analysis of the beta-tubulin gene in lung cancer.", LUNG CANCER (AMSTERDAM, NETHERLANDS) IRELAND JAN 2002, vol. 35, no. 1, January 2002 (2002-01-01), pages 11 - 16, XP002223362, ISSN: 0169-5002 *

Also Published As

Publication number Publication date
AU2001261725A1 (en) 2001-12-03
WO2001090413A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
PL356908A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002335640A1 (en) Gleason grade 4/5 prostate cancer genes
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002257033A1 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001090413A3 (en) Method and markers for prognosticating efficacy of anticancer agents
AU2002224096A1 (en) Method of testing anticancer agent-sensitivity of tumor cells
AU2001249317A1 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001266790A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2003210274A1 (en) Method for the detection of tumor markers cea, ca19.9, or ca72.4 in the stool, allowing diagnosis of gastrointestinal tumors
AU2001294999A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP